Skip to main content

Optimizing treatment
requires all the answers

Get the complete picture before choosing treatment.

Guideline-recommended testing for solid tumors1-13

ALK ATM BRAF BRAF V600E BRAF V600K BRCA1 BRCA2 CDK12 EGFR ERBB2 (HER2) ESR1 FGFR2 FGFR3 IDH1 KIT KRAS MET MSI NRAS NTRK PDGFRA PIK3CA RET ROS1
There are FDA-approved therapies available for all solid tumors with NTRK fusions and MSI status.
Current as of September 2020

Targeted treatment improves outcomes.

Patients with targetable alterations experience higher response rates to targeted therapy vs. immunotherapy.1

Targeted therapy has 56-83% response rates, vs. 4-26% response rates for immunotherapy. Targeted therapy has 56-83% response rates, vs. 4-26% response rates for immunotherapy.

Liquid biopsy offers critical advantages over tissue testing.

Leading with liquid-first testing can help inform clinical decisions faster than tissue.

Liquid biopsy begins with a minimally-invasive blood draw and delivers complete genomic results in 7 days. Tissue testing is an unpredictable process involving multiple care team members, causing up to 21 days of diagnostic delays.

Liquid biopsy begins with a minimally-invasive blood draw and delivers complete genomic results in 7 days. Tissue testing is an unpredictable process involving multiple care team members, causing up to 21 days of diagnostic delays.

You might also be interested in:

Enhance Your Practice with Guardant360 CDx

Make Guardant360 CDx a routine part of care

Learn More

Precise and Rapid Advanced Cancer Treatment Selection

How Guardant360 CDx can help determine the most appropriate treatment

Read Now

Optimizing Advanced Cancer Treatment Using Complete Genomic Profiling

The latest webinar from our Peer Education Program

Watch Now